

Form PTO-1449



Docket No. 131561200100

Appl. No. 09/434,345

INFORMATION DISCLOSURE  
STATEMENT

(use several sheets if necessary)

Applicant(s)

Teni BOULIKAS

Filing Date: November 5, 1999

Group Art Unit: 1615

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
B	1.	02/28/95	5,393,530	Schneider et al.			
J	2.	04/13/99	5,894,060	Boulikas			
J	3.	08/31/99	5,945,122	Abra et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO

## OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
B	4.	Boulikas, T., "Evolutionary consequences of nonrandom damage and repair of chromatin domains" <i>J. Mol. Evol.</i> 35:156-180 (1992).
	5.	Boulikas, T., "DNA lesion-recognizing proteins and the p53 connection" <i>Anticancer Res.</i> 16:225-242 (1996).
	6.	Boulikas, T., "Status of gene therapy in 1997: Molecular mechanisms, disease targets, and clinical applications" <i>Gene Ther. Mol. Biol.</i> 1:1-172 (1998).
	7.	Boulikas, T., "Nucleocytoplasmic trafficking: implications for the nuclear import of plasmid DNA during gene therapy" <i>Gene Ther. Mol. Biol.</i> 1:713-740 (1998).
	8.	Decout, A. et al., "Contribution of the hydrophobicity gradient to the secondary structure and activity of fusogenic peptides" <i>Mol. Membr. Biol.</i> 16(3):237-246 (1999).
	9.	Duguid, J.G. et al., "A physicochemical approach for predicting the effectiveness of peptide-based gene delivery systems for use in plasmid-based gene therapy" <i>Biophys. J.</i> 74:2802-2814 (1998).
	10.	Farhood, H. et al., "Cationic liposomes for direct gene transfer in therapy of cancer and other diseases" <i>Ann. N.Y. Acad. Sci.</i> 716:23-35 (1994).
	11.	Kim, J.C. et al., "Synthesis and antitumor evaluation of <i>cis</i> -(1,2-diaminoethane) dichloroplatinum (II) complexes linked to 5- and 6-methylneuracil and -uridine analogues" <i>Arch. Pharm. Res.</i> 21(4):465-469 (1998).
	12.	Martin, F. and Boulikas, T., "The challenge of liposomes in gene therapy" <i>Gene Ther. Mol. Biol.</i> 1:173-214 (1998).
J	13.	Martin, I. and Ruysschaert, J-M., "Comparison of lipid vesicle fusion induced by the putative fusion peptide of fertilin (a protein active in sperm-egg fusion) and the NH2-terminal domain of the HIV2 gp41" <i>FEBS Lett.</i> 405(3):351-355 (1997).


EXAMINER:

DATE CONSIDERED:

8/6/01

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449



Docket No. 131561200100

Appl. No. 09/434,345

INFORMATION DISCLOSURE  
STATEMENT

Applicant(s)

Teni BOULIKAS

(use several sheets if necessary)

Filing Date: November 5, 1999

Group Art Unit: 1615

- |     |  |
|-----|--|
| 14. | Martin, I. et al., "Membrane fusion induced by a short fusogenic peptide is assessed by its insertion and orientation into target bilayers" <i>Biochemistry</i> 38(29):9337-9347 (1999).                         |
| 15. | Morikawa, K. et al., "Synthesis of platinum complexes of 2-aminomethylpyrrolidine derivatives for use as carrier ligands and their antitumor activities" <i>Chem. Pharm. Bull. (Tokyo)</i> 38(4):930-935 (1990). |
| 16. | Papadopoulou, M.V. et al., "NLCQ-1, a novel hypoxic cytotoxin: Potentiation of melphalan, cisDDP and cyclophosphamide <i>in vivo</i> " <i>Int. J. Radiation Oncol. Biol. Phys.</i> 42(4):775-779 (1998).         |
| 17. | Pécheur, E.I. et al., "Membrane anchorage brings about fusogenic properties in a short synthetic peptide" <i>Biochemistry</i> 36(13):3773-3781 (1997).   |
| 18. | Stathopoulos, G.P. et al., "Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin" <i>Oncol. Rep.</i> 6(4):797-800 (1999). |
| 19. | Zhang, M. et al. "Studies on Cisplatin Albumin Microspheres for Lung Targeting" <i>Acta Pharmaceutica Sinica</i> 29 (5):380-386 English Abstract on p. 386 (1994).   |

*John**8/6/01*


EXAMINER:

DATE CONSIDERED:

*8/6/01*

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449



Docket No. 131561200100

Appl. No. 09/434,345

Aff 3  
Applicant(s)

Teni Boulikas

INFORMATION DISCLOSURE  
STATEMENT

(use several sheets if necessary)

Filing Date: November 5, 1999

Group Art Unit: 1615

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.						
	2.						
	3.						

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
	4.						
	5.						
	6.						

## OTHER DOCUMENTS

(including author, title, date, pertinent pages, etc.)

Examiner Initials	Ref. No.	Title
DR	7.	Boulikas, T., "The Nonuniform Repair of Active and Inactive Chromatin Domains" <i>Int. J. Onco.</i> 8:65-75 (1996).
	8.	Boulikas, T., "A Unified Model Explaining the Preferential Repair of Active Over Inactive Genes and of the Transcribed Over the Nontranscribed Strand: A Leading Role for Transcription Factors and Matrix Anchorage" <i>Int. J. Oncol.</i> 8:77-84 (1996).
	9.	Boulikas, T., "Status of Gene Therapy in 1997: Molecular Mechanisms, Disease Targets, and Clinical Applications" <i>Gene Ther. Mol. Biol.</i> 1:1-172 (1998).
	10.	Boulikas, T., "Nucleocytoplasmic Trafficking: Implications for the Nuclear Import of Plasmid DNA During Gene Therapy" <i>Gen. Ther. Mol. Biol.</i> 1:713-740 (1988).
DR	11.	Martin, F. et al., "The Challenge of Liposomes in Gene Therapy" <i>Gene Ther. Mol. Biol.</i> 1:173-214 (1988).
	12.	
	13.	
	14.	
	15.	
	16.	
	17.	
	18.	
	19.	
	20.	
	21.	
	22.	

EXAMINER:

DATE CONSIDERED:

8/6/01

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

154157.1

181597v1

Sheet 1 of 1

EXAMINER: <i>[Signature]</i>	DATE CONSIDERED: <i>8/6/01</i>
------------------------------	--------------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.